ecancermedicalscience

Case Report

Atezolizumab-induced neuromuscular syndrome mimicking myasthenia gravis in a patient with hepatocellular carcinoma – an area of concern

17 Jul 2025
Mirza Rameez Samar, Mohammad Saad Salim Naviwala, Faryal Raza Abdy, Mehwish Shahzadi

Background: Atezolizumab is an immune checkpoint inhibitor that has been approved for several neoplasms including advanced hepatocellular carcinoma. It is also capable of inducing adverse events involving the nervous system in susceptible individuals.

Case presentation: We report a case of myasthenia gravis, occurring in a 64-year-old patient diagnosed with hepatocellular carcinoma, who within a few months of the first-line combination use of Atezolizumab and Bevacizumab, developed worsening muscular weakness. She was managed with plasma exchange and intravenous immunoglobulin with minimal response initially, but later on, deteriorated and succumbed to the condition.

Conclusion: Although uncommon, the use of Atezolizumab can either give rise to or worsen a pre-existing, latent neurological condition. These neurological immune-mediated adverse events can prove to be debilitating or even life-threatening if not timely treated, thus warranting prompt investigation by the physicians for proper diagnosis and management.

Related Articles

Manuel Bazan, Claudia Gutiérrez-Villamil, Amalia Peix, Saurabh Malhotra, Fernando Dettori, Roberto N Agüero, Belén Flores, Claudio Tinoco Mesquita, Enrique Hiplan, Teresa Massardo, Isabel Berrocal, José A Coss, Verónica Gómez, María C Fonseca, Karla Abadí, Adriana Puente, Víctor Rosales, Luis F Chen, Yariela Herrera, Marina Arnal, Aurelio Mendoza, Omar Alonso, Jorge E Aguiar, Carla Cueva, Enrique Estrada, Diana Páez
Sudarshan Govender, Tamsin K Phillips, Fiona M Walter, Sarah Day, Bothwell Guzha, Suzanne E Scott, Zvavahera M Chirenje, John E Ataguba, Nomonde Mbatani, Nazia Fakie, Jennifer Moodley